BACKGROUND: Longitudinal associations between patterns of crack cocaine use and progression of HIV-1 disease are poorly understood, especially among women. This study explores relationships between crack use and HIV-1 disease outcomes in a multicenter cohort of infected women. METHODS: Subjects were 1686 HIV-seropositive women enrolled at six US research centers in the Women's Interagency HIV Study. Approximately 80% were non-white and 29% used crack during the study period. Cox survival and random regression analysis examined biannual observations made April 1996 through September 2004. Outcome measures included death due to AIDS-related causes, CD4 cell count, HIV-1 RNA level, and newly acquired AIDS-defining illnesses. RESULTS: Persistent crack users were over three times as likely as non-users to die from AIDS-related causes, controlling for use of HAART self-reported at 95% or higher adherence, problem drinking, age, race, income, education, illness duration, study site, and baseline virologic and immunologic indicators. Persistent crack users and intermittent users in active and abstinent phases showed greater CD4 cell loss and higher HIV-1 RNA levels controlling for the same covariates. Persistent and intermittent crack users were more likely than non-users to develop new AIDS-defining illnesses controlling for identical confounds. These results persisted when controlling for heroin use, tobacco smoking, depressive symptoms, hepatitis C virus coinfection, and injection drug use. CONCLUSION: Use of crack cocaine independently predicts AIDS-related mortality, immunologic and virologic markers of HIV-1 disease progression, and development of AIDS-defining illnesses among women.
BACKGROUND: Longitudinal associations between patterns of crack cocaine use and progression of HIV-1 disease are poorly understood, especially among women. This study explores relationships between crack use and HIV-1 disease outcomes in a multicenter cohort of infected women. METHODS: Subjects were 1686 HIV-seropositivewomen enrolled at six US research centers in the Women's Interagency HIV Study. Approximately 80% were non-white and 29% used crack during the study period. Cox survival and random regression analysis examined biannual observations made April 1996 through September 2004. Outcome measures included death due to AIDS-related causes, CD4 cell count, HIV-1 RNA level, and newly acquired AIDS-defining illnesses. RESULTS: Persistent crack users were over three times as likely as non-users to die from AIDS-related causes, controlling for use of HAART self-reported at 95% or higher adherence, problem drinking, age, race, income, education, illness duration, study site, and baseline virologic and immunologic indicators. Persistent crack users and intermittent users in active and abstinent phases showed greater CD4 cell loss and higher HIV-1 RNA levels controlling for the same covariates. Persistent and intermittent crack users were more likely than non-users to develop new AIDS-defining illnesses controlling for identical confounds. These results persisted when controlling for heroin use, tobacco smoking, depressive symptoms, hepatitis C virus coinfection, and injection drug use. CONCLUSION: Use of crack cocaine independently predicts AIDS-related mortality, immunologic and virologic markers of HIV-1 disease progression, and development of AIDS-defining illnesses among women.
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: Lorna E Thorpe; Margaret Frederick; Jane Pitt; Irene Cheng; D Heather Watts; Shelley Buschur; Karen Green; Carmen Zorrilla; Sheldon H Landesman; Ronald C Hershow Journal: J Acquir Immune Defic Syndr Date: 2004-11-01 Impact factor: 3.731
Authors: Anne M Rompalo; Nina Shah; Joseph B Margolick; Homayoon Farzadegan; Julia Arnsten; Paula Schuman; Josiah D Rich; Lytt I Gardner; Dawn K Smith; David Vlahov Journal: Int J STD AIDS Date: 2004-05 Impact factor: 1.359
Authors: Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: M Reuel Friedman; Ron Stall; Anthony J Silvestre; Chongyi Wei; Steve Shoptaw; Amy Herrick; Pamela J Surkan; Linda Teplin; Michael W Plankey Journal: AIDS Date: 2015-06-01 Impact factor: 4.177
Authors: Catherine R Lesko; Alexander P Keil; Richard D Moore; Geetanjali Chander; Anthony T Fojo; Bryan Lau Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 4.897
Authors: Matthew J Mimiaga; Elizabeth F Closson; David W Pantalone; Steven A Safren; Jennifer A Mitty Journal: Psychol Health Med Date: 2018-09-13 Impact factor: 2.423
Authors: Adam W Carrico; Peter W Hunt; Torsten B Neilands; Samantha E Dilworth; Jeffrey N Martin; Steven G Deeks; Elise D Riley Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2016-09-22 Impact factor: 3.455
Authors: Mardge H Cohen; Anna L Hotton; Ronald C Hershow; Alexandra Levine; Peter Bacchetti; Elizabeth T Golub; Kathryn Anastos; Mary Young; Deborah Gustafson; Kathleen M Weber Journal: J Acquir Immune Defic Syndr Date: 2015-12-15 Impact factor: 3.731